| 18 April 2018

New Team Member at Retina International

http://www.retina-international.org/

Retina International is delighted to announce the appointment of Sarah McLoughlin as Science Communication Officer.

Sarah will be working on the implementation of RI’s communications strategy where she will play a key role in one of the organisations primary objectives: delivery of the latest information on relevant developments in research and innovation to members and stakeholders.


| 06 April 2018

Retina International Supports World Health Day - April 7, 2018

http://www.retina-international.org/

On World Health Day 2018, April 7th, the World Health Organization marks its 70th anniversary. Over the past seven decades, WHO has spearheaded efforts to rid the world of diseases like smallpox and to fight against deadly habits like tobacco use.

In 2018 World Health Day is dedicated to one of WHO’s founding principles:

 “The enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, and political belief, economic or social condition.”


| 05 March 2018

Industry News: Nightstar Therapeutics Announces Initiation of STAR Phase 3 Registrational Trial for NSR-REP1 in Choroideremia

Nightstar Therapeutics plc, a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the initiation of the company’s STAR Phase 3 registrational trial to study the safety and efficacy of NSR-REP1 in patients with choroideremia. In data from 32 patients treated with NSR-REP1 across four open-label Phase 1/2 clinical trials, over 90% of treated patients maintained or improved their visual acuity over a one-year follow-up period. 


| 27 February 2018

Over 3,500 Downloads of App for Vision Impaired Community

ViaOpta Hello Application

ViaOpta Hello is a multi-tool application that can assist blind or visually impaired people by using cognitive services and Microsoft latest image analysis technology to identify people, items, and scenes.


| 13 February 2018

Foundation Fighting Blindness and ProQR enter into partnership for Usher's Type 2A

Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A 12

Foundation Fighting Blindness and ProQR have entered into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting Blindness will provide milestone-based co-funding of up to $7.5 million to ProQR to advance the program into the clinic. QR-421a received orphan drug designation from the FDA.


| 29 January 2018

Retina International World Congress 2018 in Auckland, February 7-11, One week to go !

Report by Fraser Alexander & local organising committee 

The biennial Retina International World Congress will be held in Auckland, from February 7th to 11th 2018. Now while you might be thinking that is still a whole year away, let’s remember just how quickly the last year flew by and think about making plans early!


| 29 January 2018

Retina International World Congress 2018 in Auckland, February 7-11, One week to go !

Report by Fraser Alexander & local organising committee 

The biennial Retina International World Congress will be held in Auckland, from February 7th to 11th 2018. Now while you might be thinking that is still a whole year away, let’s remember just how quickly the last year flew by and think about making plans early!


| 04 January 2018

Spark Therapeutics INC announce models of patient access to LUXTURNA

On Wednesday January 3rd 2018,  Spark Therapeutics INC announced a series of payment models designed to help the process of patient access to its new gene therapy LUXTURNA in the United States, which is the only country where the once in a lifetime therapy is currently approved.  The company also announced the cost of the treatment.

Join Our Mailing List